Amedica Corporation Announces Unexpected Passing of Former Chairman of the Board Max E. Link, Ph.D.

SALT LAKE CITY, Oct. 13, 2014 (GLOBE NEWSWIRE) -- Amedica Corporation (Nasdaq:AMDA), a biomaterial company focused on silicon nitride ceramics as a material platform to develop, manufacture and commercialize novel medical devices, today announced that Max E. Link, Ph.D., its former Chairman of the Board of Directors, passed away unexpectedly at the age of 74.

"We are deeply saddened by the passing of our friend, colleague and trusted advisor Dr. Max Link," said Dr. Sonny Bal, Chairman and CEO of Amedica Corporation. "We extend our condolences and heartfelt sympathies to his family and friends during this difficult time. We're grateful for the important contributions Max made to our Company and Board for more than a decade. His dedication and passion will be greatly missed by all at Amedica."

Dr. Link served as the Company's Chairman of the Board of Directors from October 2003 until his retirement in August 2014. During his distinguished career, Dr. Link played a pivotal role as Director and Chairman in several distinguished companies in the healthcare and biopharmaceutical fields.

About Amedica Corporation

Amedica is a company focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of orthopaedic bearings for hip and knee arthroplasty. Amedica operates an ISO 13485 certified manufacturing facility and its spine products are FDA cleared, CE marked, and currently marketed in the U.S. and select markets in Europe and South America.

The Company's web site for news releases and other information is www.amedica.com.

Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995.  Forward-looking statements contained in this press release include the intent, belief or current expectations of Amedica and members of its management team with respect to Amedica's future business operations as well as the assumptions upon which such statements are based. Forward-looking statements include specifically, but are not limited to, Amedica's market opportunities, growth, future products, market acceptance of its products, sales and financial results and such statements are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use of Amedica's products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 31, 2014, and in Amedica's other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

CONTACT: Mike Houston
         Director of Investor Relations
         801-839-3534
         mhouston@amedica.com

Released October 13, 2014